Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | GAA | P10253 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11182249 | 0.82 | MAPT (0.57) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL16671107 | 0.80 | MAPT (0.63) | MAPTGAAALDH1A1MAPK1MEN1 | |
| Ammonia Solution, Strong SCHEMBL6698890 | 0.78 | MAPT (0.61) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL3011500 | 0.77 | MAPT (0.59) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL28367079 | 0.77 | MAPT (0.61) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL8085505 | 0.74 | MAPT (0.50) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL18235938 | 0.74 | GAA (0.67) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL11528609 | 0.74 | ALDH1A1 (0.56) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL633443 | 0.73 | ALDH1A1 (0.60) | MAPTGAAALDH1A1MAPK1MEN1 | |
| SCHEMBL3141547 | 0.73 | ALDH1A1 (0.60) | MAPTGAAALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642357-B2 | Iridium complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20090036696-A1 | IRIDIUM COMPLEXES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1685092-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036696-A1 | IRIDIUM COMPLEXES | HAX1, MLX, H1-0 | MAPT 4800/4885GAA 2381/4885ALDH1A1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.